茲卡病毒藥物市場規模、佔有率及成長分析（按疫苗類型、按檢測類型、按最終用戶、按地區）- 產業預測（2025-2032）

2023 年全球茲卡病毒治療市場規模為 20 億美元，預計將從 2024 年的 22.7 億美元成長到 2032 年的 63 億美元，預測期間（2025-2032 年）的複合年成長率為 13.6%。

由於感染率上升、藥物研發持續進行以及預防和疫苗接種意識不斷增強，全球茲卡病毒藥物市場正在經歷顯著成長。茲卡主要透過蚊子傳播，會導致嚴重的出生缺陷和神經系統問題，尤其是在熱帶地區，這進一步推動了需求。 mRNA 技術和數位監控工具等技術進步正在加速疫苗的開發和安全性。例如，Moderna 的創新 mRNA-1893 疫苗目前正在進行臨床試驗，旨在不使用活株有效對抗病毒。此外，人工智慧、機器學習和區塊鏈技術的整合正在提高疫苗生產和分發的效率。這些創新透過建立信任、推廣有效治療和教育大眾，重建了對茲卡藥物治療的需求。

目錄

介紹

• 分析目的
• 市場覆蓋
• 定義

分析方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與約束

執行摘要

• 市場概況與展望
• 供需趨勢分析
• 按細分市場進行機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場觀察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場魅力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球茲卡病毒藥物市場規模及各疫苗類型複合年成長率（2025-2032）

• 市場概覽
• 去活化病毒疫苗
• 減毒活疫苗
• DNA疫苗
• mRNA疫苗

全球茲卡病毒藥物市場規模及複合年成長率（按檢測類型分類）（2025-2032 年）

• 市場概覽
• 分子檢測
• 血清學檢測

全球茲卡病毒藥物市場規模及最終用戶複合年成長率（2025-2032）

• 市場概覽
• 醫院和診所
• 研究機構

全球茲卡病毒藥物市場規模及按分銷管道分類的複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 網路藥局

全球茲卡病毒治療市場規模及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭格局

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要企業採取的策略
• 近期市場趨勢
• 主要企業市場佔有率（2024年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Moderna Inc.（USA）
• Valneva SE（France）
• Inovio Pharmaceuticals, Inc.（USA）
• Emergent BioSolutions Inc.（USA）
• Novavax, Inc.（USA）
• Johnson & Johnson（USA）
• Pfizer Inc.（USA）
• Bharat Biotech International Ltd.（India）
• GeoVax Labs, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• GlaxoSmithKline plc（GSK）（UK）
• BioCryst Pharmaceuticals, Inc.（USA）
• Zydus Cadila（India）
• GeneOne Life Science Inc.（South Korea）
• Kimer Med（Spain）
• BioVaxys Technology Corporation（Canada）
• Creative Diagnostics（USA）
• Indian Immunologicals Limited（India）
• Sanofi Pasteur（France）

結論和建議

Global Zika Virus Therapeutics Market size was valued at USD 2.0 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 6.3 billion by 2032, growing at a CAGR of 13.6% during the forecast period (2025-2032).

The global Zika virus therapeutics market is witnessing significant growth due to rising infection rates, ongoing pharmaceutical research and development, and heightened awareness surrounding prevention and vaccination. Primarily transmitted by mosquitoes, Zika causes severe birth defects and neurological issues, particularly in tropical regions, further driving demand. Technological advancements, such as mRNA technology and digital monitoring tools, have accelerated the development and safety of vaccines. For example, Moderna's innovative mRNA-1893 vaccine is currently in clinical trials, aiming to efficiently combat the virus without utilizing live strains. Additionally, the integration of AI, machine learning, and blockchain technology is enhancing vaccine production and distribution efficiency. These innovations are building trust, promoting effective treatments, and educating the public, reshaping demand in the Zika therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Zika Virus Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Zika Virus Therapeutics Market Segments Analysis

Global Zika Virus Therapeutics Market is segmented by Vaccine Type, Test Type, End User, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Virus Vaccine, Live Attenuated Vaccine, DNA Vaccine and mRNA Vaccine. Based on Test Type, the market is segmented into Molecular Test and Serological Test. Based on End User, the market is segmented into Hospitals and Clinics and Research Institutes. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Zika Virus Therapeutics Market

The rising incidence of Zika virus, especially in tropical and subtropical areas, is driving the growth of the global Zika virus therapeutics market. Factors such as increased global travel, climate change, urbanization, and the expanding mosquito population are intensifying the need for effective prevention and treatment measures. In response to this growing threat, governments and international health organizations are making substantial investments in Zika virus prevention strategies, further boosting the demand for therapeutics. This surge in investment and awareness is critical in addressing the escalating challenges posed by the Zika virus on public health.

Restraints in the Global Zika Virus Therapeutics Market

The global Zika virus therapeutics market faces significant restraints primarily due to the high costs associated with the development process. These expenses arise from the intricate nature of research and development, along with the necessity for multiple clinical trials prior to vaccine introduction. Additionally, varying acceptance criteria set by regulatory bodies such as the ICMRA in India, the FDA in the United States, and the European Union necessitate ongoing research and heavier investments. Furthermore, many vaccines demand cold storage and efficient cold chain logistics, which subsequently elevate operational costs, thereby posing additional challenges in bringing effective therapeutics to market.

Market Trends of the Global Zika Virus Therapeutics Market

The Global Zika Virus Therapeutics market is witnessing a significant trend towards the advancement of vaccine technologies, particularly with the emergence of mRNA and DNA platforms. These innovative technologies enable faster and more efficient vaccine development, allowing companies to respond swiftly to outbreaks. The accelerated approval process by regulatory bodies, coupled with the growing endorsement from medical organizations, fosters greater acceptance and confidence in these vaccines among the public. As global health agencies prioritize Zika virus prevention, the market is poised for robust growth, driven by enhanced research activities, collaborative efforts, and increased investment in novel therapeutic solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Zika Virus Therapeutics Market Size by Vaccine Type & CAGR (2025-2032)

• Market Overview
• Inactivated Virus Vaccine
• Live Attenuated Vaccine
• DNA Vaccine
• mRNA Vaccine

Global Zika Virus Therapeutics Market Size by Test Type & CAGR (2025-2032)

• Market Overview
• Molecular Test
• Serological Test

Global Zika Virus Therapeutics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Research Institutes

Global Zika Virus Therapeutics Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Zika Virus Therapeutics Market Size & CAGR (2025-2032)

• North America (Vaccine Type, Test Type, End User, Distribution Channel)
  • US
  • Canada
• Europe (Vaccine Type, Test Type, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Test Type, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Test Type, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Test Type, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Moderna Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valneva SE (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inovio Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novavax, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Biotech International Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeoVax Labs, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (GSK) (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneOne Life Science Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kimer Med (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioVaxys Technology Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Diagnostics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi Pasteur (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations